EC
JNCE

EcoR1 Capital’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

EcoR1 Capital’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-258,457
Closed -$5.68M – 43
2017
Q1 		$5.68M Buy
+258,457
New +$5.48M 1.44% 15

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital's JNCE Position: Q2 2017 in Review

EcoR1 Capital sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2017, closing a stake of 258,457 shares — an estimated $5.68M sold.

EcoR1 Capital first reported a position in JNCE in Q1 2017 and held it in 1 quarter. The position peaked at $5.68M in Q1 2017. 72 funds tracked by Wall St. Rank hold JNCE as of Q2 2017.

  • EcoR1 Capital reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • EcoR1 Capital sold 258,457 Jounce Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $5.68M.
  • EcoR1 Capital first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • EcoR1 Capital's Jounce Therapeutics, Inc. Common Stock position peaked at $5.68M in Q1 2017.
  • 72 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2017.

Based on EcoR1 Capital's 13F filing for Q2 2017, filed 14 Aug 2017.